NH vs. GMDAQ, NOVN, ZCMD, AGRX, QNRX, SNOA, NIVF, CYTO, DYNT, and EIGR
Should you be buying NantHealth stock or one of its competitors? The main competitors of NantHealth include Gamida Cell (GMDAQ), Novan (NOVN), Zhongchao (ZCMD), Agile Therapeutics (AGRX), Quoin Pharmaceuticals (QNRX), Sonoma Pharmaceuticals (SNOA), NewGenIvf Group (NIVF), Altamira Therapeutics (CYTO), Dynatronics (DYNT), and Eiger BioPharmaceuticals (EIGR). These companies are all part of the "medical" sector.
Gamida Cell (NASDAQ:GMDAQ) and NantHealth (NASDAQ:NH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.
50.3% of Gamida Cell shares are owned by institutional investors. Comparatively, 4.5% of NantHealth shares are owned by institutional investors. 6.7% of Gamida Cell shares are owned by company insiders. Comparatively, 61.3% of NantHealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Gamida Cell has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, NantHealth has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.
Gamida Cell has a net margin of 0.00% compared to Gamida Cell's net margin of -94.67%.
NantHealth received 271 more outperform votes than Gamida Cell when rated by MarketBeat users.
In the previous week, NantHealth had 3 more articles in the media than Gamida Cell. MarketBeat recorded 3 mentions for NantHealth and 0 mentions for Gamida Cell. Gamida Cell's average media sentiment score of 0.31 beat NantHealth's score of 0.00 indicating that NantHealth is being referred to more favorably in the news media.
Gamida Cell has higher earnings, but lower revenue than NantHealth. NantHealth is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.
Summary
NantHealth beats Gamida Cell on 7 of the 13 factors compared between the two stocks.
Get NantHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for NH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NantHealth Competitors List
Related Companies and Tools
